Inducible T-cell kinase (ITK)

Inducible T-cell kinase (ITK) is a member of the Tec family of non-receptor tyrosine kinases highly expressed in T-lymphocytes and related hematopoietic cells[4][5][7]. ITK plays a central role in T-cell receptor (TCR) signaling, where it is necessary for the activation of phospholipase C-gamma and downstream signaling cascades that control T-cell activation, differentiation (notably Th2 and Th17 lineage), and cytokine gene expression[2][4][7]. ITK also helps regulate the development and effector function of conventional and innate-like T-cells, influencing adaptive immunity and inflammatory responses[2][3]. Dysregulation or loss of ITK can result in immune dysfunction, affecting conditions such as immunodeficiencies, inflammatory diseases, or predisposition to certain lymphoid malignancies[5][7][9]. Small molecule ITK inhibitors are under development for indications such as autoimmune diseases, allergic inflammation, and hematologic malignancies, with soquelitinib (CPI-818) as an example of a clinical candidate[4]. ITK is part of the broader Tec kinase family, which includes several other kinases with partially overlapping roles in blood cell signaling[1][5][8].

Other names

Interleukin-2-inducible T-cell kinaseTSKEMTEmtPSCTK4

Inhibition of kinase catalytic activity, Blockade of T-cell receptor signaling pathway, Suppression of phospholipase C-gamma activation